A Pilot, Double-masked, Vehicle-controlled, Randomized Study to Evaluate the Safety and Tolerability of QLS-111 Versus Vehicle in Combination With Latanoprost Treatment in Subjects With Open-angle Glaucoma and/or Ocular Hypertension
Latest Information Update: 27 Jun 2025
At a glance
- Drugs QLS 111 (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions
- Acronyms Qlaris Study
- Sponsors Qlaris Bio
Most Recent Events
- 23 Jun 2025 According to Qlaris Bio media release, data from this study will be presented at the 2025 World Glaucoma Congress (WGC) held June 25-28, 2025, in Honolulu, Hawaii.
- 05 Feb 2025 Results presented in the Qlaris Bio media release.
- 20 Jan 2025 Status changed from recruiting to completed.